BPC-157 [Peptide]

What is BPC-157?

BPC-157 (Body Protection Compound-157), also known by its clinical designations Bepecin and PL 14736, is a synthetic 15-amino acid pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). It was derived from a partial sequence of a protective protein found in human gastric juice and was first characterised in the laboratory of Professor Predrag Sikiric at the University of Zagreb, Croatia, where the majority of published BPC-157 research has since been conducted. The compound's name refers to its position in a series of body protection compounds isolated from gastric juice fractions during systematic screening of gastric proteins for cytoprotective properties.

BPC-157 has been investigated across a broad range of preclinical rodent models for its effects on tissue repair signalling, angiogenesis, gastrointestinal mucosal cytoprotection, nitric oxide pathway modulation, and growth factor receptor upregulation. It is notable for its triple proline cluster (Pro-Pro-Pro at positions 3–5), which confers resistance to gastric proteolytic degradation, supporting its original characterisation as a stable gastric peptide. The compound has been evaluated in human clinical trials for inflammatory bowel disease, though no FDA approval has been received for any indication.

An important research context note: a systematic review published in 2025 identified that over 80% of all published BPC-157 PubMed records originate from a single research group (Sikiric et al., University of Zagreb), which limits assessment of independent multi-centre replication for reported findings. Researchers should account for this concentration of authorship when evaluating the strength of evidence for BPC-157's mechanistic claims.

BPC-157 is not approved by the Food and Drug Administration for human or veterinary use. It is not a dietary supplement and is not intended for human consumption or therapeutic self-administration. All RCDbio research compounds are supplied strictly for laboratory and research purposes only.

Chemical Properties

How Does BPC-157 Work?

BPC-157's pharmacological activity in preclinical models has been characterised through multiple intersecting pathways, with VEGF/VEGFR2 signalling and nitric oxide pathway modulation as the primary reported mechanisms. All findings originate predominantly from the Sikiric research group; independent replication across multiple research centres is limited.

VEGF/VEGFR2 Signalling Pathway

In preclinical rodent wound model preparations and isolated endothelial cell cultures, BPC-157 has been associated with upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) on endothelial cells and activation of downstream signalling cascades, including AKT-eNOS phosphorylation and ERK1/2 activation [Hsieh et al., 2020]. This VEGFR2-mediated angiogenic signalling is proposed as a primary mechanistic basis for the enhanced neovascularisation observed at wound sites in rodent BPC-157 studies. BPC-157 has also been reported to upregulate VEGF expression in fibroblast preparations, potentially creating an autocrine/paracrine angiogenic signalling loop in wound repair model systems.

Nitric Oxide Synthase Pathway Modulation

BPC-157 has been extensively investigated for bidirectional modulation of the nitric oxide (NO) signalling pathway in preclinical rodent preparations. The compound has been reported to attenuate NO overproduction under inflammatory conditions while preserving or enhancing NO availability in ischaemic tissue preparations — a dual effect attributed to context-dependent NOS isoform selectivity. In the Sikiric group's research programme, both NOS inhibition (L-NAME pre-treatment) reversal and NOS activation responses have been reported, depending on the experimental model and tissue preparation.

Growth Hormone Receptor (GHR) Pathway

In isolated human fibroblast cell preparations, BPC-157 exposure has been reported to upregulate growth hormone receptor (GHR) mRNA and protein expression, with subsequent JAK2-STAT5 signalling cascade activation [Sikiric et al., 2018]. This GHR upregulation mechanism is proposed as a complementary pathway to VEGFR2 signalling in BPC-157's observed tissue repair effects in preclinical wound models.

FAK-Paxillin Signalling and Cell Migration

In fibroblast cell culture preparations, BPC-157 has been associated with phosphorylation of focal adhesion kinase (FAK) and paxillin, components of the focal adhesion signalling complex that regulate cell migration and cytoskeletal organisation. This FAK-paxillin pathway activation has been proposed as a mechanism for BPC-157's reported effects on fibroblast migration into wound beds in preclinical model systems.

Key Research Findings

In preclinical and in vitro research contexts, BPC-157 has been associated with the following observations. The majority of findings originate from a single research group; independent replication is limited.

• VEGFR2 and AKT-eNOS activation: VEGFR2 upregulation with downstream AKT phosphorylation and eNOS activation observed in endothelial cell preparations and rodent wound model preparations [Hsieh et al., 2020].

• GHR upregulation: Growth hormone receptor mRNA and protein upregulation with JAK2-STAT5 activation observed in isolated human fibroblast preparations [Sikiric et al., 2018].

• Gastrointestinal mucosal cytoprotection: Protection against NSAID-induced gastric mucosal damage, alcohol-induced injury, and experimental IBD lesions observed in rodent in vivo preparations at doses of 10–100 μg/kg.

• Dose-dependent tissue healing effects: Accelerated healing in rodent models of skin wound, muscle tear, tendon and ligament injury observed at doses as low as 10 μg/kg in published Sikiric group studies.

• Research concentration caveat (2025 systematic review): Over 80% of BPC-157 published literature identified as originating from a single research group; independent multi-centre replication of mechanistic and efficacy findings is limited.

All findings listed above are derived from preclinical in vitro and in vivo data, predominantly from one research group. No regulatory-grade human clinical trial data have been established for BPC-157. These observations do not constitute evidence of efficacy or safety in any human condition or organism.

What are the Potential Research Applications of BPC-157?

In controlled laboratory environments, BPC-157 has been investigated for the following research applications. These do not constitute claims of efficacy or safety in any organism.

VEGF/VEGFR2 and Angiogenesis Research BPC-157 is employed in studies characterising VEGFR2 signalling pathway activation in isolated endothelial cell preparations, capillary tube formation assays, and rodent wound model neovascularisation studies. Research examines the relationship between BPC-157 concentration and VEGFR2-mediated signalling cascade activation in endothelial biology experimental systems.

Nitric Oxide Pathway Pharmacology In rodent in vivo models and isolated cell preparations, BPC-157 is investigated as a tool for studying NO pathway modulation under inflammatory and ischaemic conditions. Research examines bidirectional NOS interaction profiles and the relationship between NO availability and observed tissue protection outcomes.

Gastrointestinal Mucosal Biology Research BPC-157 is employed in NSAID-induced ulcer models, ethanol-induced gastric injury preparations, and experimental inflammatory bowel disease systems to characterise gastric cytoprotection mechanisms and mucosal integrity maintenance under chemically induced stress conditions.

Musculoskeletal Tissue Repair Models In rodent models of tendon, ligament, and muscle injury, BPC-157 is investigated for effects on collagen synthesis, inflammatory marker profiles, and tissue healing kinetics. Research examines the relationship between VEGFR2 activation and improved vascular density at injury sites.

Comparative Angiogenic Peptide Pharmacology BPC-157 is employed in comparative studies examining angiogenic peptide mechanisms alongside GHK-Cu, TB-500, and growth factor preparations, characterising how different angiogenic pathway activation profiles contribute to observed tissue repair outcomes in matched experimental systems.

What are the Potential Side Effects of BPC-157?

The following observations are derived from Sikiric group preclinical data. Independent toxicity characterisation is limited.

• No lethal dose (LD1) obtained in Sikiric group rodent toxicity studies at doses up to 2 g/kg; however, independent multi-centre toxicity characterisation is absent from the published literature

• Short plasma half-life (7.9–30 minutes in rats) means acute exposure in preclinical models is time-limited, reducing sustained-effect risk in standard research protocols

• No significant organ-level toxicity reported in published preclinical studies at research-relevant doses

• Preclinical rodent studies have not reported significant adverse effects at doses used in wound healing and gastrointestinal protection research

• No human safety or tolerability data have been established for research-grade BPC-157. These observations should not be extrapolated to human or animal outcomes.

Risk & Handling

Handling Precautions

BPC-157 should only be handled by trained laboratory personnel. Appropriate PPE is required: nitrile gloves, a laboratory coat, and eye protection at a minimum. When working with lyophilized powder, use within a laminar flow cabinet. Avoid aerosol generation during reconstitution.

Exposure Risks

Risk Tier: LOW–MODERATE

BPC-157 has demonstrated a generally low acute toxicity profile in published preclinical rodent studies. Its pharmacological activity at VEGFR2, NO synthase, and GHR pathways means accidental systemic exposure may produce pharmacological effects in tissues expressing relevant targets. The absence of independent safety data across multiple research centres warrants handling with caution, appropriate to a compound with limited multi-centre characterisation. No human safety data has been established.

Storage

• Lyophilized form: Store at −20°C in original sealed, light-protected container with desiccant

• Reconstituted form: Store at 4°C; use within 48–72 hours of reconstitution

• Do not subject to repeated freeze-thaw cycles

• The triple Pro-Pro-Pro sequence confers inherent protease resistance; standard peptide storage conditions apply

Frequently Asked Questions

Q: What is BPC-157, and what is it investigated for in research? A: BPC-157 (GEPPPGKPADDAGLV) is a synthetic 15-amino acid pentadecapeptide derived from a partial sequence of human gastric juice protein. It is investigated in preclinical research contexts for VEGF/VEGFR2 angiogenic signalling, nitric oxide pathway modulation, growth hormone receptor upregulation, gastrointestinal mucosal cytoprotection, and tissue repair pathway research. The majority of published research originates from the Sikiric group. It is not approved by the FDA and is intended strictly for laboratory research purposes.

Q: Why is the BPC-157 literature concentration in one research group a concern? A: A 2025 systematic review found that over 80% of all published BPC-157 records originate from the Sikiric group at the University of Zagreb. While this reflects sustained and productive investigation, it means independent multi-centre replication of key findings is limited — affecting the overall strength of evidence relative to compounds studied across multiple independent programmes. This is not a criticism of the Sikiric group's work, but a context researchers should understand when designing protocols and interpreting reported findings.

Q: What is the half-life of BPC-157 in preclinical models? A: The elimination half-life of BPC-157 in rat IV and IM administration is approximately 7.9–30 minutes, based on preclinical pharmacokinetic data. This short half-life reflects rapid peptide clearance under standard research conditions. The triple Pro-Pro-Pro sequence provides some inherent protease resistance, particularly against gastric enzymes — consistent with BPC-157's origin as a gastric juice protein fragment.

Q: Is BPC-157 FDA-approved? A: No. BPC-157 has been evaluated in human clinical trials for IBD-related indications but has not received FDA approval for any indication. It is prohibited under WADA S0. Research-grade BPC-157 from RCDbio is intended strictly for laboratory research purposes.

Q: How should BPC-157 be stored? A: Lyophilized BPC-157 should be stored at −20°C in a sealed, light-protected container with desiccant. Once reconstituted, store at 4°C and use within 48–72 hours. Avoid repeated freeze-thaw cycles. Visit RCD Bio to explore our full research compound catalog.